Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
NCT02050321 · University of Arizona · PHASE2 · terminated · last registry update 2018-12-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Pharmaceutical company pulled support for the trial.” | – | Registry record, University of Arizona |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RXRB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-11-12Results posted on the registry: Bausch Health Americas, Inc., Bexarotene (NCT01007448)
- 2019-06-26Results posted on the registry: University of Utah, Acitretin 25Mg Oral Capsule + Tazarotene 0.1% Gel,Top (NCT01094717)
- 2019-06-26Also stopped (terminated): University of Utah, Acitretin 25Mg Oral Capsule + Tazarotene 0.1% Gel,Top (NCT01094717)
- 2019-03-06Results posted on the registry: Dartmouth-Hitchcock Medical Center, Bexarotene (targretin) + Bexarotene (targretin) (NCT00153842)
- 2019-03-06Also stopped (terminated): Dartmouth-Hitchcock Medical Center, Bexarotene (targretin) + Bexarotene (targretin) (NCT00153842)
- 2018-11-13Results posted on the registry: Konstantin Dragnev, erlotinib and bexarotene (NCT00125359)
- 2018-11-13Results posted on the registry: Dartmouth-Hitchcock Medical Center, erlotinib (Tarceva) and bexarotene (Targretin) (NCT00125372)
- 2018-10-18Also stopped (terminated): University of Washington, vorinostat (NCT00958074)
- 2018-09-05Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, sargramostim + bexarotene (NCT00425477)
- 2018-08-16Results posted on the registry: Memorial Sloan Kettering Cancer Center, Targretin® (bexarotene) + pegylated liposomal doxorubicin hydrochloride (NCT00255801)
- 2018-07-19Also stopped (withdrawn): Günther Hofbauer, Chemopreventive application (Acitretin) (NCT00488384)
- 2018-07-09Also stopped (terminated): European Organisation for Research and Treatment of Cancer - EORTC, bexarotene + methoxypsoralen (NCT00056056)
- 2018-03-16Results posted on the registry: Millennium Pharmaceuticals, Inc., Brentuximab Vedotin + Methotrexate (NCT01578499)
- 2018-02-05Results posted on the registry: K. Lieb, Acitretin + Placebo (NCT01078168)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision